Operator: Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Cytek Biosciences, Inc. fourth quarter 2025 ...

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.07 per share a year ago. These figures ...

Guidance Cytek Biosciences sees FY 2026 revenue of $205.00M-$212.00M versus the analyst consensus of $207.40M. Cytek Biosciences’s stock price closed at $4.41. It is down -21.95% in the last 3 months ...

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial ...

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results ...

“Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said Wenbin Jiang, CEO of Cytek Biosciences. “As we ...

Cytek Biosciences has reported relatively small net losses, indicating that its financial position has not deteriorated significantly. In Q2 2025, the company had liquid assets of $262.02 million.

FREMONT, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the second quarter 2025 ...

Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Ayyoun is a staff writer who loves all things gaming and tech. His journey into the realm of gaming began with a PlayStation 1 but he chose PC as his platform of choice. With over 6 years of ...